Objective-High-sensitivity C-reactive protein (hsCRP) levels are closely associated with abdominal obesity, metabolic syndrome, and atherosclerotic cardiovascular disease. The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial has encouraged using hsCRP Ն2 mg/L to guide statin therapy; however, the association of hsCRP and atherosclerosis, independent of obesity, remains unknown. Methods and Results-We studied 6760 participants from the Multi-Ethnic Study of Atherosclerosis (MESA). Participants were stratified into 4 groups: nonobese/low hsCRP, nonobese/high hsCRP, obese/low hsCRP, and obese/high hsCRP.
H igh-sensitivity C-reactive protein (hsCRP) is an inflammatory marker that is closely associated with abdominal obesity, 1 metabolic syndrome, 2 and atherosclerotic cardiovascular disease (CVD). 3 The recent Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial has encouraged the use of hsCRP Ն2 mg/L as a screening tool for statin therapy. 4 This approach is useful for identifying increased absolute risk, 5, 6 although the mechanism of increased cardiovascular risk associated with hsCRP and its relationship to obesity remain unclear.
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Indeed, although hsCRP has previously been described as having an independent mechanistic role in atherosclerosis, 7 several lines of evidence call into question a causal role for C-reactive protein (CRP). 8 For example, a large populationbased study 9 and a mendelian randomization study 10 have not supported a causal association of hsCRP with atherosclerosis. In prior studies of subclinical atherosclerosis, variable or negative associations have been seen with inflammatory markers, [11] [12] [13] [14] whereas measures of overweight and obesity have been strongly associated with atherosclerosis. [15] [16] [17] [18] In the wake of the JUPITER trial, a more thorough understanding of hsCRP is required. To further explore the implications of hsCRP as an indicator of increased risk, we conducted a stratified analysis describing the relationship between obesity, high hsCRP, and subclinical atherosclerosis using data from the Multi-Ethnic Study of Atherosclerosis (MESA).
Methods

MESA
We used baseline data from the National Institutes of Health/ National Heart, Lung, and Blood Institute-funded MESA (2000 to 2002) . The MESA study design and participant recruitment have been previously published. 19 In summary, MESA enrolled 6814 men and women from 4 different ethnic groups (whites, Chinese, black, and Hispanic), aged 45 to 84, into a population-based prospective cohort study aimed at describing the prevalence, progression, and significance of subclinical atherosclerosis. Patients were enrolled from 6 geographically distinct centers in the United States. All participants were free of known CVD at enrollment.
All participants gave informed consent, and the study was approved by the institutional review boards at all 6 MESA field centers.
Patient Population
All MESA participants had anthropomorphic measurements of obesity taken at baseline. A total of 6762 (99%) individuals had baseline measurement of hsCRP. At baseline (2000 to 2002) , all participants received 2 baseline cardiac computed tomography (CT) scans for the evaluation of coronary artery calcium (CAC), and 6726 (99%) had a baseline carotid ultrasound for measurement of carotid intima-media thickness (cIMT). Patients without baseline hsCRP or cIMT measurements were more likely to be female and black.
For subsequent analyses, we identified a subset of our study who fit JUPITER entry criteria (retaining the low-hsCRP group for this analysis): men aged 50 and above, women aged 60 and above, low-density lipoprotein cholesterol (LDL-C) Ͻ130 mg/dL, not on lipid-lowering therapy, free of diabetes, triglycerides Յ500 mg/dL, and creatinine Յ2 mg/dL. At baseline, 417 men were younger than 50 years old, 1546 women were younger than 60 years old, 2167 participants had LDL-C Ն130 mg/dL, 1101 were on lipid-lowering therapy, 971 had diabetes, 34 had triglycerides Ն500 mg/dL, and 34 had a creatinine Ͼ2 mg/dL. Excluding these individuals resulted in a MESA JUPITER subpopulation of 2083 participants (see study flow diagram in the Supplemental Figure, available online at http://atvb.ahajournals.org).
Definition of Obesity and Metabolic Syndrome
Obesity was defined as a body mass index (BMI) Ն30 kg/m 2 or a waist circumference Ͼ102 cm for males and Ͼ88 cm for females when BMI was Ն25 kg/m 2 . Overweight was defined as BMI 25 to 29.9 kg/m 2 .
The metabolic syndrome was identified according to the modified National Cholesterol Education Program Adult Treatment Panel III definition. In summary, at least 3 of the following 5 criteria must be met: waist circumference Ͼ102 cm in males and Ͼ88 cm in females; fasting glucose Ն100 mg/dL or on hypoglycemic therapy; highdensity lipoprotein cholesterol (HDL-C) Ͻ40 mg/dL in men and Ͻ50 mg/dL in women; triglycerides Ն150 mg/dL; and systolic blood pressure Ն130 mm Hg, diastolic blood pressure Ն85 mm Hg, or on antihypertensive medication. Metabolic syndrome score is the total number of National Cholesterol Education Program Adult Treatment Panel III criteria present.
hsCRP and Study Covariates
hsCRP was determined by BNII nephelometer (N High Sensitivity CRP, Dade Behring Inc, Deerfield, IL). The lower limit of detection was 0.17 mg/L. As established by the JUPITER trial, hsCRP Ն2 mg/L was considered elevated.
Family history was obtained by asking the participants whether any immediate family member (parents, siblings, and children) had a prior myocardial infarction. Participants were classified as current cigarette smokers, former smokers, or never smokers. Medication use was defined as present use of prescription medications for the treatment of hypertension or hypercholesterolemia.
Using a Dinamap Pro 1000 automated oscillometric sphygmomanometer (Critikon), resting blood pressure was measured 3 times, with the participant in the seated position. The average of the last 2 measures was used in the analyses. A central laboratory (University of Vermont, Burlington, VT) measured levels of total and HDL-C, triglycerides, plasma glucose, and hsCRP in blood samples obtained after a 12-hour fast. Diabetes was defined according to American Diabetes Association guidelines as a fasting plasma glucose level Ͼ126 mg/dL or a history of medical treatment for diabetes. Replacement of smoking and diabetes with pack-years and fasting glucose in the study models resulted in minimal change, with no overall impact on study conclusions.
Cardiac CT Protocol
Cardiac CT was performed at 3 sites using a cardiac-gated electronbeam CT scanner (Imatron C-150XL, GE-Imatron, San Francisco, CA) and at 3 sites using a 4-slice multidetector CT instrument. All participants were scanned over phantoms of known physical calcium concentration. Patients were scanned twice, and scores were averaged. Images were read at the MESA CT reading center (Harbor-University of California, Los Angeles).
The MESA scanning protocol has been described previously. 20 Image slices were obtained with the participant supine, with no couch angulation, during a single breath hold. A minimum of 35 contiguous images were obtained, beginning above the left main coronary artery and proceeding below both ventricles. Section thickness of 3 mm, field of view 35 cm, and matrix 512ϫ512 were used to reconstruct the raw data. Nominal section thickness was 3.0 mm for electron beam CT and 2.5 mm for 4-detector row CT. Spatial resolution, expressed as the smallest voxel able to be discriminated, was 1.38 mm 3 (0.68ϫ0.68ϫ3.00 mm) for electron beam CT and 1.15 mm 3 (0.68ϫ0.68ϫ2.50 mm) for 4-detector row CT. The statistic for agreement on presence of CAC was 0.92, and the mean rescan percentage absolute difference in CAC Ͼ0 was 20.1%.
For this study, CAC was considered both as a binary measure (present versus not present) and a continuous measure (Agatston score).
Carotid Ultrasound
The right and left common carotid arteries were imaged by trained technicians according to a common scanning protocol using high resolution B-mode ultrasonography with a Logiq 700 machine (General Electric Medical Systems, Waukesha, Wisconsin). The MESA ultrasound reading center (Tufts Medical Center) measured maximal intima-media thickness of the common carotid artery as the mean of the maximum intima-media thickness of the near and far walls on the right and left sides.
For this study, cIMT was considered both as a binary measure (Ͼ75th percentile among MESA participants, as suggested in some guidelines 21 ) and as continuous measure.
Statistical Analysis
We divided our total and MESA JUPITER populations into 4 study groups: group 1, nonobese, hsCRP Ͻ2 mg/L (reference group); group 2, nonobese, hsCRP Ն2 mg/L; group 3, obese, hsCRP Ͻ2 mg/L; group 4, obese, hsCRP Ն2 mg/L. For secondary analyses, similar study groups were constructed stratifying by National Cholesterol Education Program Adult Treatment Panel III metabolic syndrome in place of obesity.
We analyzed baseline characteristics of the study participants according to the 4 main study groups. Frequencies and proportions were reported for categorical variables, and either means with standard deviations or medians with interquartile ranges were reported for continuous variables based on normality of distribution. 2 tests, Fisher exact tests, 1-way ANOVA, or Kruskal-Wallis tests were used for comparison of variables between groups. To examine correlations, a Spearman correlation matrix between BMI, waist circumference, and hsCRP was constructed.
Multivariable regression models were used to determine the independent associations between our study groups and subclinical atherosclerosis. When considering measures of subclinical atherosclerosis as categorical variables, we conducted prevalence regres-sion using a generalized estimating equation with logit link and binomial distribution. The measure of association from this model was interpreted as the prevalence ratio. When considering measures of subclinical atherosclerosis as continuous variables, we used robust linear regression.
Multivariable analyses were conducted in 3 groups: total study population (age, gender, race adjusted), MESA JUPITER population (age, gender, race adjusted), MESA JUPITER population (fully adjusted model). The fully adjusted model included the following covariates: age, gender, race, systolic blood pressure, diastolic blood pressure, smoking (never/former/current), LDL-C, HDL-C, triglycerides, and antihypertensive medications. Additional models were conducted including BMI and hsCRP as continuous measures to adjust for the possibility of residual confounding. Interaction terms for age, gender, and race were tested, and they were discarded because of nonsignificance. Education, a measure of socioeconomic status, was tested in the models but discarded because of lack of significance.
To confirm the prognostic significance of our findings, we also constructed age-, gender-, and race-adjusted Cox proportional hazards models for our 4 study groups for the prediction of coronary heart disease (CHD) and CVD events. CHD events consisted of myocardial infarction, death from CHD, definite angina, probable angina followed by coronary revascularization, or resuscitated cardiac arrest. CVD events consisted of myocardial infarction, angina, resuscitated cardiac arrest, stroke (not transient ischemic attack), CHD death, stroke death, other atherosclerotic death, or other CVD death. A complete description of the MESA follow-up methods is available at http://www.mesa-nhlbi.org.
All analyses used a 5%, 2-sided significance level. Calculations were performed using Stata software, version 8.2.
Results
Baseline Characteristics: Entire MESA Population
The mean age of the 6760 study participants was 62Ϯ10 years. Approximately 53% were female, with a mean calculated 10-year Framingham risk for the entire cohort of 8.2Ϯ7%. The mean BMI was 28.3Ϯ5.5 kg/m 2 , and median hsCRP was 1.9 mg/L (0.84 to 4.26). Approximately 52% were obese, and 48% had high hsCRP.
In general, females were more likely to be obese and have high hsCRP. For females, 25% were nonobese with low hsCRP, whereas 43% of males fit into this group. Approximately 44% of females were both obese and had high hsCRP, whereas just 22% of males fit this group (Figure 1) .
The number of participants in the 4 study groups and their characteristics are shown in Table 1 . Patients in the obese, high-hsCRP group were more likely to be black and have hypertension, diabetes, and a family history of myocardial infarction. In this group, levels of HDL-C were lower and triglyceride levels were higher, which is characteristic of increasing metabolic syndrome prevalence. However the traditional 10-year Framingham risk score for CHD, which does not include obesity, hsCRP, or metabolic syndrome, was slightly lower in this group. The number of JUPITER-eligible participants in the 4 study groups is shown in Figure 1 .
Both obesity and subclinical inflammation are considered central features of the metabolic syndrome. Therefore, we conducted a focused comparison of metabolic variables between the nonobese, high-hsCRP group (group 2) and the obese, low-hsCRP group (group 3). Participants in the obese, low-hsCRP group were more likely to have features of the metabolic syndrome than the nonobese, low-hsCRP group. Fasting glucose, blood pressure, and triglycerides were higher and HDL-C lower in this group, corresponding to more features of the metabolic syndrome.
Correlation of BMI, Waist Circumference, and hsCRP: Entire MESA Population
BMI and hsCRP were found to be correlated (Spearman rank correlation coefficient 0.42, PϽ0.0001). There was a greater correlation between anthropomorphic measures of obesity and hsCRP among women compared with men ( Table 2 ). In women, the correlation coefficient between BMI and hsCRP was ϭ0.48 (PϽ0.0001), and between waist circumference and hsCRP it was ϭ0.44 (PϽ0.0001). For men, these correlation coefficients were ϭ0.35 and ϭ0.37, respectively (PϽ0.0001, gender/BMI interaction term PϽ0.0001).
Stated in clinically applicable terms, there was a 71% probability that obese females had high hsCRP. When hsCRP was high, approximately 77% of females were found to be obese. For males, the probabilities were 53% and 56%, respectively. Table 3 shows the results of the primary multivariable analyses. The reference group for these analyses was the nonobese, low-hsCRP group (group 1). After adjustment for age, race, and gender, individuals in group 2 (nonobese, high hsCRP) had a minimal association with CAC Ͼ0, which was not apparent in the MESA JUPITER subpopulation (prevalence ratio 1.11, 95% CI 0.85 to 1.47). In contrast, individuals in group 3 (obese, low hsCRP) had a strong association with CAC Ͼ0, which remained similar in the MESA JUPITER population (prevalence ratio 1.68, 95% CI 1.26 to 2.22). Among MESA JUPITER individuals in group 4 (obese, high hsCRP), the prevalence ratio was 1.28 (95% CI 1.00 to 1.64), consistent with no multiplicative interaction between obesity and high hsCRP.
Association between Obesity, hsCRP, and Subclinical Atherosclerosis
Adjusted for age, race, and gender, individuals in group 2 (nonobese, high hsCRP) had a modestly increased prevalence ratio for cIMT Ͼ75th percentile that was similar, but no longer significant, in the MESA JUPITER subpopulation (prevalence ratio 1.35, 95% CI 0.99 to 1.83). In contrast, in group 3 (obese, low hsCRP) there was a persistent statistically significant increase in cIMT (prevalence ratio 1.43, 95% CI 1.05 to 1.95) among the MESA JUPITER population. The prevalence ratio for the MESA JUPITER population in group 4 (obese, hsCRP) was 2.33 (95% CI 1.78 to 3.05). Formal testing revealed no evidence of multiplicative interaction (Pϭ0.35) between obesity and high hsCRP. All individual correlation coefficients were statistically significant at PϽ0.001.
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Similar trends were seen when CAC was considered as a continuous variable (Table 3 ). Group 2 (nonobese, high hsCRP) was not associated with CAC. Within group 3 (obese, low hsCRP), there was a strong association with CAC (␤ϭ0.63, 95% CI 0.32 to 0.93). In group 4, when both obesity and high hsCRP were present, the ␤ϭ0.47 (95% CI 0.20 to 0.74), indicating no multiplicative interaction.
Similar trends were also seen when cIMT was considered as a continuous variable (Table 3 ). Group 2 (nonobese, high hsCRP) was mildly associated with increased cIMT (␤ϭ0.37, 95% CI 0.18 to 0.55). Within group 3 (obese, low hsCRP), there was a moderate association with cIMT (␤ϭ0.50, 95% CI 0.31 to 0.69). The strongest absolute difference was seen when both obesity and high hsCRP were present (group 4: ␤ϭ0.68, 95% CI 0.51 to 0.85). Formal testing revealed no evidence of multiplicative interaction (Pϭ0.56) between obesity and high hsCRP.
The results for the fully adjusted model in the total population are shown in Supplemental Table I . We also conducted similar analyses after substituting overweight for obesity ( Supplemental Table II ). Overall results and conclusions were similar to the analyses using obesity described above. Table 4 shows the results of the multivariable analysis stratifying by hsCRP status and presence of metabolic syndrome. In general, results were similar to those above stratifying by hsCRP and obesity. High hsCRP was associated with cIMT but not CAC in the absence of metabolic syndrome. Metabolic syndrome was strongly correlated with both CAC and cIMT. When both metabolic syndrome and cIMT were present, there was no evidence of multiplicative interaction. Figure 2 summarizes the age and gender-adjusted prevalence ratios for the 4 study groups in graphical form (MESA JUPITER subpopulation).
Association of Metabolic Syndrome, hsCRP, and Subclinical Atherosclerosis
No Residual Confounding With Exposure Dichotomization or Gender Interaction
When anthropomorphic variables and hsCRP were included into the models as continuous variables, hsCRP was not significantly associated with either CAC or cIMT, whereas BMI and waist circumference were significantly associated with both CAC and cIMT. There was no statistically significant interaction between the 4 main study groups and age (study groupϫage, Pϭ0. 14) , gender (study groupϫgender, Pϭ0.41), or race (study groupϫrace, Pϭ0.56) in the prediction of subclinical atherosclerosis among MESA JUPITER participants.
No Effect Modification by JUPITER Inclusion/Exclusion Criteria
LDL-C greater than or less 130 mg/dL, use of cholesterollowering therapy, and diabetes status were not statistically significant effect modifiers of the association between hsCRP and subclinical atherosclerosis. ␤-Coefficient should be interpreted as the absolute difference between each category and the reference category. *MESA JUPITER population (Nϭ2083): men aged Ն50 and women aged Ն60 with LDL-C Ͻ130 mg/dL, not on lipid-lowering therapy, without diabetes, triglycerides Յ500 mg/dL, and creatinine Յ2 mg/dL. †Adjusted for age, gender, race, systolic blood pressure, diastolic blood pressure, smoking, LDL-C, HDL-C, triglycerides, and antihypertensive medications.
Median follow-up of the participants was 5.8 years. Within the MESA JUPITER population, there were 82 CHD events and 117 CVD events in all. Trends were similar to those seen for subclinical atherosclerosis, although results did not achieve statistical significance because of limited power. The multivariable adjusted hazard ratios for CHD and CVD events for group 2 (nonobese, high hsCRP) were 0.88 (95% CI 0.46 to 1.73) and 1.05 (95% CI 0.59 to 1.90), respectively. For group 3 (obese, low hsCRP), the hazard ratios for CHD and CVD events were 1.25 (95% CI 0.69 to 2.29) and 1.11 (95% CI 0.66 to 1.90), respectively, and for group 4 (obese, high hsCRP), they were 1.33 (95% CI 0.73 to 2.32) and 1.39 (95% CI 0.87 to 2.21). . MS indicates metabolic syndrome; CIMT, carotid intima-media thickness. In models adjusted for age, gender, and race, hsCRP Ն2 was weakly associated with subclinical atherosclerosis in the absence of obesity or metabolic syndrome. In contrast, obesity and metabolic syndrome were associated with increased atherosclerosis independently of hsCRP status. There was no multiplicative interaction between hsCRP, obesity/metabolic syndrome, and CAC or cIMT.
Discussion
In this large multiethnic cohort of participants free of baseline clinical CVD, high hsCRP in the absence of obesity was not associated with CAC and was mildly associated with cIMT. Obesity was strongly associated with CAC and cIMT independently of hsCRP. When obesity and high hsCRP were both present, there was no evidence of multiplicative interaction. Similar associations were seen in when considering only the MESA JUPITER subpopulation.
Obesity and hsCRP
One proposed mechanistic link between obesity and the development of atherosclerosis is subclinical inflammation, resulting from innate and acquired immune responses. 22, 23 CRP is an acute phase plasma protein that is synthesized in the liver in response to inflammatory cytokines and therefore is used as a nonspecific marker of inflammation. Our study (ϭ0.42) confirms the close correlation between measures of obesity and hsCRP seen in other, more homogenous cohorts. 1 Indeed, among more than 19 000 participants in the Reasons for Geographic and Racial Differences in Stroke study, obesity was more strongly correlated with elevated hsCRP than any other demographic or clinical variable. 24 Results from our study indicate that circulating levels of hsCRP do not fully account for the association between obesity and atherosclerosis. As illustrated by the metabolic syndrome clinical phenotype, the vascular biology of obesity is complex, with links to several other emerging atherosclerotic risk factors, including prediabetes, atherogenic dyslipidemia, decreased adiponectin, leptin resistance, decreased plasminogen activator inhibitor-1, and endothelial dysfunction, including microalbuminuria. 25, 26 In our study, the addition of hsCRP as the sole marker of inflammation did not add to the association between the metabolic syndrome and subclinical atherosclerosis.
Inflammation, hsCRP, and Atherosclerosis
Although there is a clear role for hsCRP in cardiovascular risk prediction independent of obesity and physical fitness, 27, 28 there is currently controversy over whether CRP plays a causal role in atherosclerotic CVD. 8, 29 Studies supporting a causal role point to evidence that CRP binds to LDL and is present in atherosclerotic plaques. 30 However, recent basic science research has questioned a direct atherogenic mechanism. For example, direct injection of CRP into mice and rats elicits relatively little cellular level activity and little vascular inflammation. 31 Transgenic rabbits that express high amounts of human CRP have no additional aortic or coronary atherosclerosis, despite evidence of human CRP within the vessel wall. 32 Several recent large clinical studies have added to the basic science evidence suggesting that CRP is not causal. For example, Zacho et al studied a large population-based sample, showing that polymorphisms in the CRP gene are associated with marked increases in CRP levels yet do not predict the incidence of adverse ischemic cardiovascular events. 9 Elliott et al carried out a mendelian randomization study of the most closely associated single-nucleotide polymorphism in the CRP locus, as well as other well-established CRP genetic variants, among more than 100 000 patients. 10 The single-nucleotide polymorphism and other variants were associated with CRP levels but not with incidence of CHD. This suggests that hsCRP may reflect a secondary inflammatory response, and not the cause, of atherosclerosis.
Our study adds to prior studies demonstrating a weak association between hsCRP and subclinical atherosclerosis by studying a large multiethnic sample, stratifying by obesity, and including both CAC and cIMT. [11] [12] [13] [14] Because atherosclerosis underlies the development of most clinical cardiovascular events, our findings suggest that if CRP does indeed have a causal role in CVD, the mechanism for its effect likely relies on pathways other than increased subclinical atherosclerosis. Additional research is needed to define the role of CRP in nonatherosclerotic pathways, such as thrombosis, reduced fibrinolysis, and plaque instability. 8 In our study, the association of high hsCRP with cIMT Ͼ75th percentile was stronger than that seen with CAC Ͼ0. Prior studies using different cutpoints have suggested a strong association between CRP and cIMT, 33 as compared with CAC. [11] [12] [13] [14] The implications of atherosclerosis in these vascular beds may be different. The stronger association of hsCRP with cIMT may explain why some studies have found hsCRP to be more predictive of stroke than CHD. 34 Within MESA, CAC predicts all cardiovascular events (CHD, stroke, and fatal CVD) better than cIMT, although cIMT is more strongly predictive of stroke. 35 cIMT also predicts stroke better than CAC among individuals Ͼ70 years old in the Cardiovascular Health Study. 36 
The MESA JUPITER Subpopulation
In our study, there were similar mild associations between high hsCRP and subclinical atherosclerosis in the entire MESA population and in the MESA JUPITER subpopulation. Neither LDL Ͻ130, exclusion of diabetes, nor exclusion of patients on prior lipid-lowering therapy modified the relationship between hsCRP and subclinical atherosclerosis. As such, the biology of hsCRP does not appear to differ for the specific MESA JUPITER population. Because prior research indicates that high hsCRP (at least in single biomarker approaches 37 ) appears to be associated with increased absolute risk, our results suggest a continuing need to define the mechanism of hsCRP-related risk in all populations.
Limitations
This study is limited by its cross-sectional nature. Although we were able to describe the statistical associations of obesity, hsCRP, and subclinical atherosclerosis, we were unable to establish the temporal relationships or causality. Although our events analysis shows the same trends as those seen for subclinical atherosclerosis, these results must be considered exploratory given the small number of events when defining small subgroups within MESA.
Although the multiethnic makeup of this study increases generalizability, it may limit precise characterization of obesity. Waist circumference, which was an integral part of our definition of obesity, varies for different ethnicities and geographic locations. 38 The impact of different waist circumference thresholds according to ethnicity has not yet been thoroughly described within MESA. Another limitation is that hsCRP was measured just once, at baseline, in MESA.
Conclusions and Future Directions
In this study, we showed that high hsCRP as defined by JUPITER (Ն2 mg/L) was weakly associated with subclinical atherosclerosis in the absence of obesity. In contrast, obesity was associated with increased atherosclerosis independently of hsCRP status. Further research, of a longitudinal nature, is needed to understand the potential independent mechanisms of risk imparted by obesity, subclinical inflammation as measured by hsCRP, and the possibility of their synergistic combination. Based on our study, it does not appear that isolated identification of hsCRP Ն2 mg/L is an optimal tool for identifying individuals expected to have an increased burden of atherosclerosis. Identifying obesity may be more valuable for this purpose.
